Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, Leonardi GC, Plodkowski AJ, Gupta H, Cherniack AD, Tolstorukov MY, Sharma B, Felt KD, Gainor JF, Ravi A, Getz G, Schalper KA, Henick B, Forde P, Anagnostou V, Jänne PA, Van Allen EM, Nishino M, Sholl LM, Christiani DC, Lin X, Rodig SJ, Hellmann MD, Awad MM. Ricciuti B, et al. Among authors: forde p. JAMA Oncol. 2022 Aug 1;8(8):1160-1168. doi: 10.1001/jamaoncol.2022.1981. JAMA Oncol. 2022. PMID: 35708671 Free PMC article.
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM. Cottrell TR, et al. Among authors: forde pm. Ann Oncol. 2018 Aug 1;29(8):1853-1860. doi: 10.1093/annonc/mdy218. Ann Oncol. 2018. PMID: 29982279 Free PMC article. Clinical Trial.
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Forde PM, et al. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. N Engl J Med. 2022. PMID: 35403841 Free PMC article. Clinical Trial.
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, Halmos B, Goldman J, Forde P, Leuenberger K, Peled N, Kalemkerian GP, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH. Schrock AB, et al. Among authors: forde p. J Thorac Oncol. 2016 Sep;11(9):1493-502. doi: 10.1016/j.jtho.2016.06.004. Epub 2016 Jun 22. J Thorac Oncol. 2016. PMID: 27343443 Free article.
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
Mansfield AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, Patel S, Bazhenova LA, Forde P, Lou Y, Dizona P, Villaruz LC, Arnold SM, Khalil M, Kindler HL, Koczywas M, Pacheco J, Rolfo C, Xia B, Mikula E, Chen L, Patel K, Smith KER, Cao L, Shapiro G, Costello BA, Adjei A, Sharon E, Moscow JA, Zamboni W, Hassan R. Mansfield AS, et al. Among authors: forde p. Lung Cancer. 2024 Sep;195:107928. doi: 10.1016/j.lungcan.2024.107928. Epub 2024 Aug 13. Lung Cancer. 2024. PMID: 39197359 Clinical Trial.
Treatment of Pleural Mesothelioma: ASCO Guideline Update.
Kindler HL, Ismaila N, Bazhenova L, Chu Q, Churpek JE, Dagogo-Jack I, Bryan DS, Drazer MW, Forde P, Husain AN, Sauter JL, Rusch V, Bradbury PA, Cho BCJ, de Perrot M, Ghafoor A, Graham DL, Khorshid O, Lebensohn A, White J, Hassan R. Kindler HL, et al. Among authors: forde p. J Clin Oncol. 2025 Jan 8:JCO2402425. doi: 10.1200/JCO-24-02425. Online ahead of print. J Clin Oncol. 2025. PMID: 39778125
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
Awad MM, Forde PM, Girard N, Spicer J, Wang C, Lu S, Mitsudomi T, Felip E, Broderick SR, Swanson SJ, Brahmer J, Kerr K, Saylors GB, Chen KN, Gharpure V, Neely J, Balli D, Hu N, Provencio Pulla M. Awad MM, et al. Among authors: forde pm. J Clin Oncol. 2025 Jan 8:JCO2402239. doi: 10.1200/JCO-24-02239. Online ahead of print. J Clin Oncol. 2025. PMID: 39778121
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.
Rosner S, Connor S, Sanber K, Zahurak M, Zhang T, Gurumurthy I, Zeng Z, Presson B, Singh D, Rayes R, Sivapalan L, Pereira G, Ji Z, Thummalapalli R, Reuss JE, Broderick SR, Jones DR, Deutsch JS, Cottrell TR, Chaft JE, Spicer J, Taube J, Anagnostou V, Brahmer JR, Pardoll DM, Ji H, Forde PM, Marrone KA, Smith KN. Rosner S, et al. Among authors: forde pm. Clin Cancer Res. 2025 Jan 17;31(2):339-351. doi: 10.1158/1078-0432.CCR-24-2983. Clin Cancer Res. 2025. PMID: 39545922 Free PMC article.
204 results